Altasciences Continues Manufacturing Expansion in Philadelphia With Client‑Dedicated Building Project
15.7.2022 17:00:00 EEST | Business Wire | Press release
Altasciences’ formulation, manufacturing, and analytical services facilities in Philadelphia, PA, are undergoing further expansion. Altasciences—an integrated CRO/CDMO offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies—is building client‑dedicated facilities for Alladapt Immunotherapeutics, Inc. (“Alladapt”), a private, clinical-stage biopharmaceutical company developing prescription therapeutics to address IgE-mediated food allergy, with a scheduled completion time in 2023.
Having developed the formulation and manufacturing processes to meet all of Alladapt’s Phase I and II clinical trial needs, Altasciences has been contracted to continue the process with the construction of a new 53,000-square-foot building that will meet Alladapt’s Phase III and commercial requirements. Altasciences will manage all aspects of this project, including warehousing, release management, manufacturing, quality assurance, and finished product release. The new building will have additional client dedicated capacity that can be used for Phase I through to commercial manufacturing services.
“We are pleased to continue supporting Alladapt in their important goal of developing a single therapeutic to address a wide range of mono- and multi-food allergies, and we look forward to fulfilling their Phase III and commercial requirements,” stated Ben Reed, General Manager, CDMO Services at Altasciences.
“The training Altasciences provides their CDMO workforce is second to none, as each team member is well-equipped to optimize and complete our manufacturing projects. We are proud to partner with Altasciences to continue advancing the clinical development of our potentially best in-class oral immunotherapy candidate, ADP101,” said Ashley Dombkowski, Ph.D., Chief Executive Officer and co-founder at Alladapt.
About Altasciences
Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220715005047/en/
Contact information
Julie-Ann Cabana
Altasciences
+1 514 601-9763
jcabana@altasciences.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Thales Unveils a Global Framework to Protect Critical Organisations from Frontier AI Attacks1.10.2026 14:18:00 EEST | Press release
At the Thales Cyber Summit held in Paris (France) , Thales today unveiled a global response to the challenges created by Frontier AI models. Reasoning, autonomy and scale of these cutting-edge systems far exceed previous generations, and can accelerate vulnerability discovery, exploit development and cyberattack execution at machine speed. This marks a shift in AI from a tool that assists humans to one that acts autonomously, reshaping the threat landscape for organisations, the first of which those operating critical systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001459724/en/ ©Thales “Frontier AI models represent a new inflection point for cybersecurity. The challenge is not only technological; it is about helping organisations act before risks materialize, understand the implications, assess their exposure, and, if an attack still succeeds, ensure resilience and quick recovery. By combining advanced technologi
MidOcean Concludes 2026 Equity Raise, Securing More Than $4 Billion of Equity Commitments to Accelerate Global LNG Growth Strategy1.10.2026 14:00:00 EEST | Press release
MidOcean Energy ("MidOcean" or the "Company"), a liquefied natural gas (LNG) company formed and managed by EIG, today announced the conclusion of its 2026 equity capital raise, securing more than $4 billion of closed and pending commitments over the last 12 months from new strategic and institutional investors, as well as significant re-ups from existing investors. The capital committed significantly exceeded the Company's original target of $2 billion, reflecting continued confidence in MidOcean's strategy, portfolio, team and long-term growth outlook. The raise includes commitments from strategic investors, sovereign-linked institutions and financial investors. Among the new investors are the Private Department of Sheikh Mohammed bin Khalid Al Nahyan, Idemitsu Kosan, NYK Line (through Diamond Gas MidOcean), The Arab Energy Fund, Shizuoka Gas and certain Korean institutional investors. The proceeds are expected to enhance MidOcean's balance sheet flexibility and position the Company t
LISTERINE ® Launches Oral Care Counts This World Smile Day as Oral Disease Cases Rise to 3.73 Billion1.10.2026 13:45:00 EEST | Press release
Nearly half the world’s population is affected by oral disease – and the number of cases is rising. This World Smile Day, LISTERINE® is launching Oral Care Counts – a multiyear education and advocacy initiative showing why oral health is an essential part of overall health and how practical daily habits, including a three-step oral care routine of brushing, flossing and rinsing, can support better oral health.The multiyear education and advocacy campaign is designed to help more people understand the essential role oral health plays in overall health and wellbeing, and how realistic daily habits can make prevention more achievable. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001163338/en/ Oral Care Counts aims to bring together healthcare professionals, advocates, policymakers, community organizations, and consumers to raise understanding of oral health as an essential part of overall health and wellbeing. The initiati
Samsung Bioepis and Teva Expand Strategic Partnership to Advance Up to Six Potential Biosimilar Candidates1.10.2026 11:30:00 EEST | Press release
Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the companies have entered into a global license, development, and commercialization agreement for up to six potential biosimilar candidates, with two confirmed investigational biosimilar candidates, SB41, a biosimilar candidate referencing Fasenra®1 (benralizumab), and SB44, a biosimilar candidate referencing Ilaris®2 (canakinumab). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001835078/en/ Under the terms of the agreement, Samsung Bioepis will be responsible for the development, regulatory registration, and manufacture of the biosimilars, while Teva will be responsible for commercialization in global markets, including the United States (U.S.), Europe, and Canada. The companies have agreed to an option for expanding the partnership to other territories. This agreement reinforces the long-standing and successful
FPT and ZEBOX Partner to Advance AI and Sustainable Innovation in Logistics1.10.2026 11:00:00 EEST | Press release
FPT, a global technology and IT services provider, and ZEBOX, the international innovation accelerator initiated by the CMA CGM Group, have entered into a three-year strategic partnership to develop and deploy AI-powered solutions for the transport and logistics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001622214/en/ The partnership was formalized during the Vietnam - France Leaders Forum, held as part of Vietnam’s General Secretary and State President’s official visit to France. The partnership will combine FPT’s expertise in artificial intelligence, automation and large-scale digital transformation with ZEBOX’s innovation network and its close connection to the CMA CGM Group’s global transport and logistics ecosystem. The partners will focus on shipping, port operations, logistics, supply chain management and clean energy. A first joint initiative in Vietnam As a first step, FPT, ZEBOX and CMA CGM Vietnam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom